Clinical Trial Update: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Rebif, Copaxone, and Tysabri for active Relapsing Remitting Multiple Sclerosis was terminated with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)
• Rebif (interferon beta-1a)
• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2014-08-13